Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689
作者
N.Y. Lee,Douglas R. Adkins,R.I. Haddad,Tao Yu,C. Le Tourneau,William H. Westra,Rebecca D. Chernock,Makiko Tahara,Kevin J. Harrington,A. Klochikhin,R. Granado Carrasco,G.V. Alves,B.G.M. Hughes,Marc Oliva,I.P. Figueiredo Lima,Tsutomu Ueda,Cole Manschot,K.C. Benjamin,Burak Gümüşçü,R. Uppaluri